Sound Bioventures Team Photo

Sound Bioventures is a venture capital fund investing in about-to-be clinical and clinical stage private companies in Europe and the USA developing novel medicines that addresses unmet medical needs.

We lead, co-lead or follow


As co-investors, you will find us straight forward, transparent, long term oriented and asking “is this the right thing to do for the company” at every step of our decision making.

Read more about the Team

Strategy & Approach

Sound Bioventures is a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and USA developing medicines in specialty therapeutics areas.

Read more about Strategy & Approach

Why the name Sound Bioventures?

Our investment firm started as a Danish-Swedish project with our Danish founder Casper Breum and our Swedish founder Johan Kördel living on either side of “the sound”, a stretch of water between Denmark and Sweden connecting the North and Baltic seas. The name is derived from the Scandinavian Öresund (SE) or Øresund (DK). The Sound has always been one of the world’s busiest shipping lanes with approximately 40.000 ships passing through annually. The SE/DK Sound or Greater Copenhagen region is referred to as Medicon Valley and is, like the shipping lane, arguably the busiest in Scandinavia. When our US founder Bibhash Mukhopadhyay joined, our proposition to our investors and portfolio companies took on an expanded global perspective and footprint, spanning an even bigger water passage, the Atlantic Ocean.-“a super sized version of the Sound”! Sound does of course also stand for financially robust investments as well as investments that lead to a healthy body and mind.
Read more about Sound Bioventures »

NephroDI Therapeutics Announces Investment by Sound Bioventures to Accelerate Development of NDI-5001 as a Potential First-in-Class Therapy for Pediatric Orphan Kidney Disease

June 20, 2024 Seattle, WA – NephroDI Therapeutics (NephroDI), a near-clinical stage pharmaceutical company focusing on kidney disorders, announces a Series A investment from life sciences VC Sound Bioventures. together with a previously announced strategic corporate partnership, the capital will be used to advance NDI-5001, a proprietary small mole …